diabetes
Conditions
Interventions
concentrated preparation of insulin glargine The dosing period is from start of examination to implementation of the questionnaire 3~6 months after.We set the dose to the target of less than HbA1c7%
Sponsors
Osaka Saiseikai Noe Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients whose HbA1c are more than 8.0% or who are already using insulin
Exclusion criteria
Exclusion criteria: Contraindicated patient in the attached document of the insulin preparations Contraindicated patient in the attached document of diabetes drugs Hypoglycemic risk Serious heart trouble Severe hepatic dysfunction Severe renal dysfunction Internal secretion disease Needs the steroid dosage Patients judged by the investigator to be ineligible for some other reason
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in HbA1c, the body weight, the custom-built diabetes treatment satisfaction questionnaire result and adverse events including hypoglycemia at 24weeks later from an examination start | — |
Secondary
| Measure | Time frame |
|---|---|
| From an examination start, it is the following items 24 weeks later -Achievement rate of HbA1c<7.0% and<8.0% -Change in fasting blood glucose -Glycemic variability by SMBG -Change in insulin dose(daily basal insulin doses, daily total insulin doses) | — |
Countries
Japan
Contacts
Public ContactMitsuru Ota
Osaka Saiseikai Noe Hospital Department of Diabetes and Endocrinology
Outcome results
None listed